Unusual Symptoms

Lab Test Genecept Assay Report Page 3 June 25, 2015


Drug Interaction Summary;

This summary provides a listing of implications for psychotropic medications specific to your patient's genetic profile
 
Use as Directed
Therapeutic Options
Use With Caution
Medication
Primary metabolizing enzyme(s)
No known Gene-Drug Interactions
Options which may be used if clinically indicated
Serum levels may be ↑ [reduced dose may be required]
Serum levels may be ↓ [increased dose may be required]
Increased risk for adverse events or poor response
Anxiolytic
Alprazolam (Xanax®) 3A4
X
  
Buspirone (Buspar®) 3A4
X
  
Chlordiazepoxide 3A4
X
  
Clonazepam (Klonopin®) 3A4
X
  
Diazepam (Valium®) 2C19, 3A4
X
  
Hydroxyzine (Vistaril®)
-
X
  
Lorazepam (Ativan®)
-
X
  
Typical Antipsychotics
Chlorpromazine 2D6
X
  
Fluphenazine 2D6
X
  
Haloperidol (Haldol®) 2D6, 3A4
X
  
Loxapine (Loxitane®)
-
X
  
Perphenazine 2D6
X
  
Pimozide (Orap®)[4] 2D6
X
  
Promethazine 2D6
X
  
Thioridazine 2D6
X
  
Thioridazine (®) 2D6
X
  
Thiothixene (Navane®)
-
X
  
Trifluoperazine
-
X
  
Atypical Antipsychotics
Aripiprazole (Abilify®)[4] 2D6, 3A4  
X
  
X
Asenapine (Saphris®)
-
 
X
  
X
Clozapine (Clozaril®) 2D6, 3A4  
X
  
X
Iloperidone (Fanapt®) 2D6  
X
  
X
Lurasidone (Latuda®) 3A4  
X
  
X
Olanzapine (Zyprexa®) 2D6  
X
  
X
Paliperidone (Invega®)
-
  
X
  
X
Quetiapine (Seroquel®) 3A4  
X
  
X
Risperidone (Risperdal®) 2D6  
X
  
X
Ziprasidone (Geodon®)
-
  
X
  
X
Dopaminergic Stimulant Agents
Amphetamine-Dextroamphetamine (Adderall®) 2D6
X
X
  
Dexmethylphenidate (Focalin®)
-
X
X
  
Dextroamphetmine (Dexedrine®)
-
X
X
  
Lisdexamfetmine (Vyvanse®)
-
X
X
  
Methamphetamine (Desoxyn®) 2D6
X
X
  
Methylphenidate (Ritalin®)
-
X
X
  
Mood Stabilizers
Carbamazepine (Tegretol®) 3A4
X
X
  
Gabapentin (Neurontin®)
-
X
X
  
Lamotrigine (Lamictal®)
-
X
X
  
Lithium
-
X
X
  
Oxcarbazepine (Trileptal®)
-
X
X
  
Valproate (Depakote®, Depakene®)
-
X
X
  
Alternative/Complementary
Inositol (®)
-
X
X
  
L-methylfolate (Deplin®)
-
X
X
  
Omega-3-Fatty Acids(®)
-
X
X
  
SAMe (®)
-
X
 
  

[1} Prodrug - requiring activation by the liver; 2D6 IMs/PMs may experience lower efficacy and increased side effects due to reduced conversion to the active metabolite and higher levels of the inactive parent drug; 2D6 UMs may experience increased conversion of the parent drug, and higher levels of the active metabolite
[2] Indeterminate - gene drug interaction exists, but clinical impact is indeterminate or genotype could not be determined
[3] These medications are listed both as therapeutic options (due to a CACNA1C variation) and as medications to use with caution (due to the presence of a DRD2 or 5HT2C variation and the potential interaction with atypical antipsychotics). The patient's clinical presentation should be fully considered to determine risks vs. benefits of using these particular treatments.
[4] - Medication has manufacturer dose-administration FDA labeling; see the Genecept Assay Report Interpretation Guide


<- Previous Next ->